EMPAGLIFLOZIN IS MORE EFFECTIVE IN REDUCING MICROALBUMINURIA AND ALT LEVELS COMPARED WITH DAPAGLIFLOZIN: REAL LIFE EXPERIENCE

Gunhan, H.; Imre, E.; Erel, P.; Ustay, O.

doi:10.4183/aeb.2020.59

EMPAGLIFLOZIN IS MORE EFFECTIVE IN REDUCING MICROALBUMINURIA AND ALT LEVELS COMPARED WITH DAPAGLIFLOZIN: REAL LIFE EXPERIENCE

Atıf İçin Kopyala

Gunhan H. G. , Imre E., Erel P., Ustay O.

ACTA ENDOCRINOLOGICA-BUCHAREST, cilt.16, sa.1, ss.59-67, 2020 (SCI İndekslerine Giren Dergi)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 16 Konu: 1
Basım Tarihi: 2020
Doi Numarası: 10.4183/aeb.2020.59
Dergi Adı: ACTA ENDOCRINOLOGICA-BUCHAREST
Sayfa Sayıları: ss.59-67

Özet

Context. Sodium Glucose Co-Transporter-2 inhibitors (SGLT2i) are oral antidiabetic agents that can be used with insulin in the treatment of type 2 diabetes mellitus, known for cardiovascular and renal benefits. Dapagliflozin and empagliflozin are available in Turkey and we aimed to evaluate real-life data of using these two molecules with other oral antidiabetic drugs (OAD) or insulin.